Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria
- 1 September 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 33 (9) , 1767-1777
Abstract
Background: Despite reports of hematuria and proteinuria with rosuvastatin use at the time of its approval by the US Food and Drug Association (FDA), little postmarketing surveillance exists to assess real-world risk. Current labeling suggests dose reduction (maximum daily dose of 10 mg) for patients with severe CKD. Methods: Using deidentified electronic health record data, we analyzed 152,101 and 795,799 new users of rosuvastatin and atorvastatin, respectively, from 2011 to 2019. We estimated inverse probability of treatment–weighted hazard ratios (HRs) of hematuria, proteinuria, and kidney failure with replacement therapy (KFRT) associated with rosuvastatin. We reported the initial rosuvastatin dose across eGFR categories and evaluated for a dose effect on hematuria and proteinuria. Results: Overall, we identified 2.9% of patients with hematuria and 1.0% with proteinuria during a median follow-up of 3.1 years. Compared with atorvastatin, rosuvastatin was associated with increased risk of hematuria (HR, 1.08; 95% confidence interval [95% CI], 1.04 to 1.11), proteinuria (HR, 1.17; 95% CI, 1.10 to 1.25), and KFRT (HR, 1.15; 95% CI, 1.02 to 1.30). A substantial share (44%) of patients with eGFR 2 was prescribed high-dose rosuvastatin (20 or 40 mg daily). Risk was higher with higher rosuvastatin dose. Conclusions: Compared with atorvastatin, rosuvastatin was associated with increased risk of hematuria, proteinuria, and KFRT. Among patients with eGFR 2, 44% were prescribed a rosuvastatin daily dose exceeding the FDA’s recommended 10 mg daily dose. Our findings suggest the need for greater care in prescribing and monitoring rosuvastatin, particularly in patients who receive high doses or who have severe CKD.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK121825)
This publication has 37 references indexed in Scilit:
- Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?Canadian Journal of Cardiology, 2011
- Use of multiple international healthcare databases for the detection of rare drug‐associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statinsPharmacoepidemiology and Drug Safety, 2010
- The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary carePharmacoepidemiology and Drug Safety, 2008
- Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO studyPharmacoepidemiology and Drug Safety, 2006
- Variable Selection for Propensity Score ModelsAmerican Journal of Epidemiology, 2006
- Inhibitors of 3-Hydroxy-3-Methylglutaryl–CoA Reductase Reduce Receptor-Mediated Endocytosis in Opossum Kidney CellsJournal of the American Society of Nephrology, 2004
- Dangers of rosuvastatin identified before and after FDA approvalThe Lancet, 2004
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)The American Journal of Cardiology, 2003
- Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitorsMolecular Aspects of Medicine, 1994
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976